Evidence map›Paper›PMID 41065919›Full record

ReviewCurrent allergy and asthma reports2025

Using Biologics in the Prevention of Anaphylaxis.

Daniel Song, Amika K Sood, Stephen A Schworer, Onyinye I Iweala, Mildred Kwan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current allergy and asthma reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel SongDepartment of Medicine, University of North Carolina School of Medicine, 3300 Thurston Building, CB #7280, Chapel Hill, NC, 27514, USA.
Amika K SoodDivision of Rheumatology, Allergy & Immunology, University of North Carolina School of Medicine, 3300 Thurston Building, CB #7280, Chapel Hill, NC, 27514, USA.
Stephen A SchworerDivision of Rheumatology, Allergy & Immunology, University of North Carolina School of Medicine, 3300 Thurston Building, CB #7280, Chapel Hill, NC, 27514, USA.
Onyinye I IwealaDivision of Rheumatology, Allergy & Immunology, University of North Carolina School of Medicine, 3300 Thurston Building, CB #7280, Chapel Hill, NC, 27514, USA.
Mildred KwanDivision of Rheumatology, Allergy & Immunology, University of North Carolina School of Medicine, 3300 Thurston Building, CB #7280, Chapel Hill, NC, 27514, USA. mildred_kwan@med.unc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewUntil recently, the management of anaphylaxis has been dependent on the avoidance of known triggers combined with the emergent treatment of immediate and, possibly, fatal hypersensitivity reactions. The approval of omalizumab for the prevention of food-induced anaphylaxis heralds a new era for the use of biologics to curtail anaphylactic reactions in susceptible individuals. RECENT

findingsAs more knowledge is gleaned about the immunologic mechanisms of anaphylaxis, the application of biologics for prophylaxis of anaphylaxis has accelerated. While omalizumab is currently the only approved biologic for averting anaphylaxis, data is accumulating for the use of other biologics as well. These include monoclonal antibodies that target IgE, mast cell receptors, cytokines, and alarmins.

Indexed as

AnaphylaxisAnti-Allergic AgentsBiological ProductsFood HypersensitivityAntibodies, MonoclonalHumansImmunoglobulin EOmalizumabAnti-Allergic AgentsAntibodies, MonoclonalBiological ProductsImmunoglobulin EOmalizumabAnaphylaxisBiologicsDrug hypersensitivityFood allergyImmunotherapyMast cell disorders

Identifiers

PMID41065919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.